DK3681884T3 - Rad51-inhibitorer - Google Patents

Rad51-inhibitorer Download PDF

Info

Publication number
DK3681884T3
DK3681884T3 DK18782257.2T DK18782257T DK3681884T3 DK 3681884 T3 DK3681884 T3 DK 3681884T3 DK 18782257 T DK18782257 T DK 18782257T DK 3681884 T3 DK3681884 T3 DK 3681884T3
Authority
DK
Denmark
Prior art keywords
rad51 inhibitors
rad51
inhibitors
Prior art date
Application number
DK18782257.2T
Other languages
English (en)
Inventor
Alfredo C Castro
Joseph VACCA
Tyler Maclay
Casey Cameron Mccomas
Original Assignee
Cyteir Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyteir Therapeutics Inc filed Critical Cyteir Therapeutics Inc
Application granted granted Critical
Publication of DK3681884T3 publication Critical patent/DK3681884T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK18782257.2T 2017-09-11 2018-09-11 Rad51-inhibitorer DK3681884T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762556763P 2017-09-11 2017-09-11
US201862711959P 2018-07-30 2018-07-30
PCT/US2018/050391 WO2019051465A1 (en) 2017-09-11 2018-09-11 RAD51 INHIBITORS

Publications (1)

Publication Number Publication Date
DK3681884T3 true DK3681884T3 (da) 2022-08-22

Family

ID=63722779

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18782257.2T DK3681884T3 (da) 2017-09-11 2018-09-11 Rad51-inhibitorer

Country Status (21)

Country Link
US (5) US10590122B2 (da)
EP (2) EP3681884B1 (da)
JP (1) JP7265537B2 (da)
KR (1) KR102718671B1 (da)
CN (1) CN111542521B (da)
AU (1) AU2018328818C1 (da)
BR (1) BR112020004828A2 (da)
CA (1) CA3075062A1 (da)
DK (1) DK3681884T3 (da)
ES (1) ES2925218T3 (da)
HU (1) HUE059969T2 (da)
IL (2) IL273156B (da)
MX (2) MX2020002745A (da)
PH (1) PH12020550079A1 (da)
PL (1) PL3681884T3 (da)
PT (1) PT3681884T (da)
SG (2) SG11202002069WA (da)
SI (1) SI3681884T1 (da)
TW (1) TWI791608B (da)
WO (1) WO2019051465A1 (da)
ZA (1) ZA202104029B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019014315A1 (en) 2017-07-11 2019-01-17 Cyteir Therapeutics, Inc. RAD51 INHIBITORS
MX2020002745A (es) * 2017-09-11 2020-10-14 Cyteir Therapeutics Inc Inhibidores de rad51.
WO2020186006A1 (en) * 2019-03-12 2020-09-17 Cyteir Therapeutics, Inc. Rad51 inhibitors
PH12021552205A1 (en) * 2019-03-25 2022-06-13 Cyteir Therapeutics Inc Combinations of rad51 and parp inhibitors
TW202114662A (zh) * 2019-06-21 2021-04-16 美商賽堤爾醫療公司 利用rad51抑制劑治療胰臟癌之方法
EP4108663A1 (en) * 2020-02-19 2022-12-28 Simcere Pharmaceutical Co., Ltd. Substituted aryl compound
KR20220149733A (ko) * 2020-03-03 2022-11-08 사이티어 테라퓨틱스, 인크. 암을 치료하기 위한 특정 투여량의 rad51 억제제 화합물 67a(2301085-06-1)
EP4228662A4 (en) * 2020-10-13 2025-03-19 The Board of Trustees of the Leland Stanford Junior University Methods for predicting the outcomes of chimeric antigen receptor T cells in lymphomas from cell-free DNA and genetic mutations
JP2022151436A (ja) * 2021-03-26 2022-10-07 均 石井 髄膜炎と脳炎の治療薬。
WO2023078271A1 (zh) * 2021-11-02 2023-05-11 上海旭成医药科技有限公司 芳香化合物、其制备方法、中间体、药物组合物和应用
CN116196314B (zh) * 2023-05-04 2023-08-15 广州市妇女儿童医疗中心 Ri-1或其盐在制备防治胃肠道疾病的药物中的应用
WO2025038484A1 (en) 2023-08-11 2025-02-20 Cyteir Therapeutics, Inc. Method for preparing cyclohexyl thiazolyl phenyl carbamate
CN117603097B (zh) * 2023-11-29 2024-06-18 安徽泽升科技股份有限公司 一种快速制备2-溴-5-硝基苯磺酰氯的方法
EP4574144A1 (en) * 2023-12-19 2025-06-25 Gongwin Biopharm Co., Ltd. Method for treating peripheral nerve sheath tumor
WO2025137508A1 (en) * 2023-12-22 2025-06-26 Cyteir Therapeutics, Inc. Solid forms of cyclohexyl thiazolyl phenyl carbamate and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
DE69132905T2 (de) 1990-12-06 2002-08-01 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Detektion von Nukleinsäuresequenzen
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
PT2099442E (pt) * 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
AU2010331927B2 (en) 2009-12-17 2013-10-10 Merck Canada Inc. Aminopyrimidines as Syk inhibitors
US10912761B2 (en) * 2012-11-30 2021-02-09 The University Of Chicago Methods and compositions involving RAD51 inhibitors
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
WO2016140971A1 (en) 2015-03-02 2016-09-09 The Regents Of The University Of California Novel rad51 inhibitors and uses thereof
US10442817B2 (en) * 2015-06-04 2019-10-15 Drexel University Inhibitors of RAD52 recombination protein and methods using same
WO2019014315A1 (en) 2017-07-11 2019-01-17 Cyteir Therapeutics, Inc. RAD51 INHIBITORS
MX2020002745A (es) 2017-09-11 2020-10-14 Cyteir Therapeutics Inc Inhibidores de rad51.
WO2020186006A1 (en) 2019-03-12 2020-09-17 Cyteir Therapeutics, Inc. Rad51 inhibitors
PH12021552205A1 (en) * 2019-03-25 2022-06-13 Cyteir Therapeutics Inc Combinations of rad51 and parp inhibitors

Also Published As

Publication number Publication date
BR112020004828A2 (pt) 2020-12-01
KR20200105808A (ko) 2020-09-09
WO2019051465A1 (en) 2019-03-14
US20190077799A1 (en) 2019-03-14
SI3681884T1 (sl) 2022-10-28
IL293332A (en) 2022-07-01
SG11202002069WA (en) 2020-04-29
AU2018328818B2 (en) 2023-07-06
EP3681884A1 (en) 2020-07-22
US20250136591A1 (en) 2025-05-01
CN111542521B (zh) 2024-02-23
IL293332B2 (en) 2024-02-01
SG10202107087YA (en) 2021-07-29
HUE059969T2 (hu) 2023-01-28
RU2020113064A (ru) 2021-10-14
TWI791608B (zh) 2023-02-11
MX2020002745A (es) 2020-10-14
US10336746B1 (en) 2019-07-02
JP7265537B2 (ja) 2023-04-26
RU2020113064A3 (da) 2022-04-29
AU2018328818C1 (en) 2023-12-21
TW201917121A (zh) 2019-05-01
US20220056022A1 (en) 2022-02-24
PT3681884T (pt) 2022-08-12
EP3681884B1 (en) 2022-06-01
US20190194182A1 (en) 2019-06-27
EP4112616A1 (en) 2023-01-04
AU2018328818A1 (en) 2020-04-02
CA3075062A1 (en) 2019-03-14
US11084812B2 (en) 2021-08-10
CN111542521A (zh) 2020-08-14
IL293332B1 (en) 2023-10-01
KR102718671B1 (ko) 2024-10-17
US10590122B2 (en) 2020-03-17
IL273156A (en) 2020-04-30
MX2023004221A (es) 2023-04-21
US20200216437A1 (en) 2020-07-09
IL273156B (en) 2022-07-01
PL3681884T3 (pl) 2022-11-14
ES2925218T3 (es) 2022-10-14
PH12020550079A1 (en) 2020-10-05
ZA202104029B (en) 2022-07-27
JP2020533329A (ja) 2020-11-19

Similar Documents

Publication Publication Date Title
IL283639A (en) Kif18a inhibitors
IL269196A (en) Novel inhibitors
IL263586A (en) Inhibitors of the menin-mll interaction
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
DK3612525T3 (da) Pd-1-/pd-l1-inhibitorer
ZA202104029B (en) Rad51 inhibitors
IL280863A (en) Autotaxin inhibitors and uses thereof
DK3571192T3 (da) Jak1-selektive inhibitorer
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3442972T3 (da) Bromdomænehæmmere
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
EP3347008A4 (en) BETA-Lactamase INHIBITORS
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
EP3541821A4 (en) MAGL INHIBITORS
MA44006A (fr) Inhibiteur pde1
EP3394068A4 (en) TDO2 INHIBITORS
DK3630744T3 (da) Pyrazol-magl-inhibitorer
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
EP3600301A4 (en) KDM4 INHIBITORS
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
EP3454852A4 (en) PHOSPHOTIDYLINOSITOL 3-KINASES INHIBITORS